Neoadjuvant PRRT with Y-90-DOTATOC – Preliminary results from a monocentric prospective study

#3707

Introduction: Surgery is considered the only curative option in pNET but is feasible only in a minority of patients. A new possible therapeutical strategy in pNETs is preoperative Peptide Receptor Radionuclide Therapy (PRRT) in order to increase the efficacy of surgery.

Aim(s): Aim of this prospective study is to evaluate the response and rate of R0 surgery in pts with unresectable or borderline resectable G1/G2 pNETs eligible to PRRT with 90Y-DOTATOC and correlate the response to circulating NET transcripts measured before and after PRRT.

Materials and methods: To date we have enrolled 7 out 30 pts with unresectable or borderline resectable G1/G2 pNET; limited liver disease based on pre-treatment 68Ga-DOTATOC PET/CT. All the pts received at least one cycle of 1.85 GBq/cycle of 90Y-DOTATOC; the protocol foresaw a cumulative activity of 9.25-11.1 GBq in 5-6 cycles. At first cycle, each patient received 111In-OctreoScan to perform dosimetry on kidneys.

Conference:

Presenting Author: Grana C

Authors: Grana C, Papi S, Bertani E, Cascio A, Rocca P,

Keywords: PRRT, Y-90-Dotatoc, Neoadjuvant PRRT, pancreatic NET,